Title
Magnesium Sulphate and Rocuronium in Patients Over 60
Effects of Magnesium Sulphate on the Pharmacodynamics of Rocuronium in Patients 60 Years or Older: Randomised and Double-Blind Study
Phase
Phase 1Lead Sponsor
Instituto Nacional de Cancer, BrazilStudy Type
InterventionalStatus
Completed No Results PostedIndication/Condition
Head and Neck CancerIntervention/Treatment
magnesium sulfate ...Study Participants
64The purpose of this study is to evaluate the effects of MgSO4 administration on the pharmacodynamics of rocuronium in patients with 60 or more years of age.
MgSO4 30 mg/kg in 0.9% physiological saline (total volume 100 ml) intravenously, for 10 min, and then continuous intravenous infusion of MgSO4 at a rate of 1 g/h during the surgical procedure until the maximum of 3 h
100 ml of 0.9% physiological saline, for 10 min, and then continuous intravenous infusion of saline at a rate of 33 ml/h during the surgical procedure until the maximum of 3 h
In the magnesium group, patients received MgSO4 30 mg/kg in 0.9% physiological saline (total volume 100 ml) intravenously, for 10 min, and then continuous intravenous infusion of MgSO4 at a rate of 1 g/h during the surgical procedure until the maximum of 3 h.
Controls received 100 ml of 0.9% physiological saline, for 10 min, and then continuous intravenous infusion of saline at a rate of 33 ml/h during the surgical procedure until the maximum of 3 h.
Inclusion Criteria: 60 years or older ASA physical status I-III Scheduled for elective oncologic head and neck surgery Exclusion Criteria: Severe renal insufficiency (calculated creatinine clearance < 30 ml/min) Pre-operatory serum magnesium values > 2.5 mEq/l Patients receiving medications known to affect neuromuscular function (furosemide, aminoglycoside, anticonvulsivants, calcio channel blocker, litium, azatioprine, cyclofosfamide)
